Clinical Trial: A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07748208) titled 'A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes' on July 20.

Brief Summary: This study will evaluate the safety of inavolisib in combination with fulvestrant, with or without palbociclib, in participants with PIK3CA-mutated, HR+, HER2-negative ABC and type 2 diabetes.

Study Start Date: Sept. 01

Study Type: INTERVENTIONAL

Condition: Breast Cancer Diabetes Type II

Intervention: DRUG: Inavolisib

Participants will receive oral inavolisib on Days 2-28 of each 28-day cycle.

DRUG: Fulvestrant

Participants will receive intra...